Merck & Co. Cash Flow Soars Amid Profit Decline

Pharmaceutical giant Merck & Co., Inc. has reported its highest operating cash flow at USD 19,967 million in recent times, indicating a strong ability to generate cash.

This achievement is coupled with efficient inventory management, as evidenced by an inventory turnover ratio of 2.85 times. Additionally, the company's dividend per share stands at USD 5.07, reflecting its commitment to rewarding shareholders.

However, despite these positive indicators, Merck & Co., Inc. has faced significant challenges in its quarterly performance for June 2026. Pre-tax profit declined by a substantial 79.4% to USD 893 million, while net profit plummeted to USD 241 million, down 93.16%. The return on capital employed (ROCE) also registered at 6.98%, which is lower than previous periods.

The company's raw material costs increased by 5.55% year-over-year, contributing to its financial struggles. Furthermore, cash and equivalents stood at USD 12,955 million, marking a low point for the company.